Source: Radio Cardena Agraminte
January 15 2014
The therapeutic vaccine Racotumomab (Vaxira), developed by Havana’s Molecular Immunology Center (CIM) for advanced lung cancer is among Cuba’s countless scientific achievements, assert experts of that institution.
This immunogen, which began to be applied in primary health care after its registration on the island in 2012, has shown encouraging results of survival and improvement of the quality of life of patients suffering from this deadly disease.
Dr. Alina Hernandez, commercial and business manager of the company in charge of commercializing products and services of the CIM, told ACN that this product of Cuban biotechnology, used in stage four of lung cancer, is safe, has no adverse effects and is registered in Cuba and Argentina.
In recent statements, Doctor of Sciences Agustin Lage, director of this center of the BioCubaFarma business group, explained that the production capacity of Vaxira, in addition to guaranteeing the demand of Cuban patients in need of it, makes it possible to carry out clinical trials in Brazil, Argentina, Japan, Germany and Indonesia.
- Mediterranean Diet Prevents Diabetes
- Vietnam Establishes Parameters for Quality Health Care Services
- Cuba will Host World Congress on Diabetic Foot Ulcer
- Panama Continues Fighting Dengue
- Some 100,000 Children to Be Vaccinated against Polio in Angola
- Over 5 Thousand Diabetic Patients Benefitted by National Health Program
- Cuba Exhibits in Argentina Experience in Renal Transplants
- Cuban Medical Brigade’s 15 Years in Haiti: Thousands of Lives Saved
- A Deserved Tribute to All Cuban Doctors
- U.S. Scientists Create Scanner to Detect Tiny Tumors in the Body
- Third Stage of More Doctors Program Opens in Brazil
- Cuba Reduces Deaths in Children due to Heart Diseases
- Thousands Venezuelan Patients Treated in Cuba